# UNITED STATES PROVISIONAL PATENT APPLICATION

**Title:** System and Method for Stigmergic Multi-Agent Therapeutic Delivery
         with Hierarchical Large Language Model Coordination

**Inventors:** [TO BE COMPLETED — Antelligence Research Team]

**Filing Date:** [TO BE COMPLETED — Provisional Filing Date]

**Application Type:** Provisional Patent Application Under 35 U.S.C. § 111(b)

**Attorney Docket No.:** [TO BE ASSIGNED]

---

## CROSS-REFERENCE TO PRIOR DISCLOSURE

This application claims priority to and benefit from the public disclosure made
at the IEEE/ACM BSN2025 (Body Sensor Networks) conference on November 3, 2025,
under the title "Antelligence: LLM-Driven Stigmergic Nanobot Swarms for
Glioblastoma Drug Delivery" (the "BSN2025 Disclosure").

IMPORTANT NOTICE REGARDING CLAIMS SCOPE:
The BSN2025 Disclosure on November 3, 2025 included public description of the
following subject matter: the basic stigmergic pheromone communication framework
(Claim 1), and the application to glioblastoma multiforme at a high level (Claim 5,
in part). Claims 2 (blockchain audit trail), Claim 3 (zero-knowledge proofs),
Claim 4 (hierarchical dual-LLM architecture), Claim 6 (CED benchmarking method),
and Claim 7 (typed signal communication protocol) were NOT disclosed at the
BSN2025 conference and are first disclosed herein. Under 35 U.S.C. § 102(b)(1)(A),
the BSN2025 Disclosure constitutes prior art only to claims it actually disclosed.
Inventors assert that Claims 2, 3, 4, 6, and 7 as drafted remain fully novel and
non-obvious over the BSN2025 Disclosure and all other prior art known to the
inventors as of the filing date of this provisional application.

---

## BACKGROUND OF THE INVENTION

### 1. Field of the Invention

This invention relates to systems and methods for targeted therapeutic delivery
using autonomous agent swarms, and more particularly to a multi-agent artificial
intelligence framework employing stigmergic chemical signal fields as the sole
inter-agent communication primitive, coordinated by a hierarchical large language
model (LLM) architecture, with optional immutable audit logging via distributed
ledger technology.

### 2. The Clinical Problem: Glioblastoma Multiforme

Glioblastoma Multiforme (GBM) is the most aggressive primary brain tumor in adults,
with a median survival of 14-16 months from diagnosis even with optimal standard
of care (Stupp et al., 2005, N. Engl. J. Med. 352:987-996). The fundamental
challenges in GBM treatment are:

a) HETEROGENEITY: GBM contains at least four distinct cell populations:
   (i)   Cancer stem cells (CSCs), which are highly drug-resistant, self-renewing,
         and responsible for tumor recurrence;
   (ii)  Differentiated tumor cells, which proliferate rapidly;
   (iii) Drug-resistant clones, which survive chemotherapy and repopulate;
   (iv)  Invasive cells, which migrate along white matter tracts into healthy brain
         tissue and cannot be surgically resected.

b) BLOOD-BRAIN BARRIER (BBB): The tight junctions of cerebral endothelial cells
   prevent systemic delivery of most chemotherapeutic agents to therapeutic
   concentrations within the tumor parenchyma.

c) INTRATUMORAL PRESSURE: Elevated interstitial fluid pressure in GBM impedes
   passive diffusion of large molecules from vasculature into tumor.

d) RECURRENCE: Virtually all GBM tumors recur within 2 cm of the original tumor
   margin, driven by CSCs that survive initial treatment.

### 3. Current Best Practice: Convection-Enhanced Delivery (CED)

Convection-Enhanced Delivery (CED) is the current state-of-the-art surgical
technique for direct intratumoral drug delivery (Morrison et al., 1994, Cancer
Chemother. Pharmacol. 35:88-95; Linninger et al., 2008, J. Theor. Biol. 250:125-138).
CED operates by:

a) Stereotactic surgical placement of one to four catheter tips directly within
   the tumor parenchyma or surrounding brain tissue;

b) Continuous infusion of drug solution under positive hydrostatic pressure
   (typically 5 µL/min for 6 hours), creating bulk convective fluid flow that
   transports drug through the interstitial space;

c) Drug transport governed by the advection-diffusion-reaction equation:
   dC/dt = D*nabla^2(C) - v*nabla(C) - lambda*C + S
   where D is effective diffusion coefficient (~5e-8 cm2/s in brain parenchyma),
   v is interstitial fluid velocity (0.1-0.5 µm/min under CED pressure),
   lambda is drug degradation rate (~0.01/min for most chemotherapeutics),
   and S is the source term at the catheter tip.

d) The Vd/Vi ratio (distribution volume to infusion volume) of approximately 6:1,
   meaning a 1 mL infusion distributes drug over roughly 6 mL of tissue.

CRITICAL LIMITATIONS OF CED:

i)   No cell-type selectivity: Drug concentration follows the pressure/diffusion
     gradient, not the biological distribution of resistant or stem cells. CSCs
     receive no preferential drug exposure despite being the primary recurrence driver.

ii)  No feedback or adaptation: Once the catheter is surgically placed and infusion
     begins, the delivery profile is fixed. There is no mechanism to redirect drug
     toward areas of residual viable tumor detected during infusion.

iii) Surgical morbidity: Craniotomy or stereotactic burr hole surgery is required
     for each treatment cycle, with attendant infection risk, neurological
     complications, and patient burden.

iv)  BBB bypass is local and permanent: CED creates a local disruption of normal
     tissue architecture but cannot selectively target cells at the infiltrating
     tumor margin, which may be 2-4 cm from the catheter tip.

v)   Drug wastage: A substantial fraction of administered drug is cleared into
     the vasculature (blood-brain barrier clearance) or degraded before reaching
     target cells, resulting in poor therapeutic efficiency measured as tumor
     cell kills per unit drug administered.

vi)  No intelligent routing: CED cannot distinguish between necrotic core (dead
     cells requiring no treatment), hypoxic penumbra (partially viable), and
     actively proliferating viable tumor — all receive drug in proportion to
     local fluid convection, wasting therapeutic payload on already-dead tissue.

### 4. Deficiencies of Existing Multi-Agent AI Frameworks

Existing multi-agent AI frameworks such as AutoGen (Wu et al., 2023, arXiv:2308.08155),
CrewAI (CrewAI Inc., 2024), LangChain Agents (Chase, 2022), and standard swarm
robotics platforms (Dorigo et al., 2014, Swarm Intelligence 8:1-4) fail to address
the therapeutic delivery challenge for the following reasons:

a) AutoGen and CrewAI employ DIRECT agent-to-agent message passing as the primary
   coordination primitive. This requires agents to maintain persistent communication
   channels, imposes synchronization overhead, and does not scale to the thousands
   of independent agents required for whole-tumor coverage. Furthermore, direct
   communication is inappropriate in a biological substrate where agents cannot
   broadcast to each other but can only modify their local chemical environment.

b) Standard swarm robotics (stigmergy in physical robots) lacks any language-model
   reasoning capability. Agents follow fixed behavioral rules and cannot engage
   in strategic planning, interpret complex multi-modal sensor data, or adapt
   their strategy based on natural language instructions from a supervising clinician.

c) Existing biological simulation frameworks (PhysiCell, BioFVM, CompuCell3D) are
   passive simulation tools — they model cell behavior but do not incorporate
   autonomous therapeutic agents with decision-making capability.

d) No existing system combines: (i) stigmergic field-mediated coordination,
   (ii) hierarchical LLM reasoning at multiple scales, (iii) typed biochemical
   signal primitives, (iv) immutable audit logging via blockchain, and
   (v) physics-based benchmarking against clinical CED baselines.

---

## SUMMARY OF THE INVENTION

The present invention provides a system and method for targeted therapeutic
delivery in which a plurality of autonomous agents operate within a biological
substrate, coordinate exclusively through a shared stigmergic chemical signal
field (the "pheromone layer"), receive episodic strategic guidance from a
hierarchical LLM coordinator (the "Queen"), and deposit typed signal primitives
that encode path success, danger detection, and target recruitment — without any
direct peer-to-peer communication between individual agents.

In a preferred embodiment, the invention is applied to glioblastoma multiforme,
where agents navigate the tumor microenvironment, classify cells by type and
phase, and selectively deliver therapeutic payloads with cell-type-aware targeting
that is fundamentally impossible with CED.

Optional embodiments provide immutable audit logging of all agent decisions and
drug delivery events on a distributed ledger, with privacy-preserving verification
via zero-knowledge proofs that confirm simulation correctness without revealing
patient anatomical data.

The invention includes a rigorous benchmarking methodology comparing agent-based
delivery against CED using identical tumor geometry derived from clinical MRI
segmentation (BraTS dataset), enabling quantitative demonstration of therapeutic
advantage.

---

## DETAILED DESCRIPTION OF THE INVENTION

### Section A: System Architecture Overview

The system 100 comprises four principal layers:

LAYER 1 — TUMOR MICROENVIRONMENT MODEL (102):
A physics-based 2D/3D grid simulation of the tumor parenchyma, implementing:
- Substrate diffusion for oxygen, glucose, and therapeutic agents (BioFVM-inspired
  finite difference solver on a regular Cartesian grid);
- Tumor cell population with four phenotypes: stem cell, differentiated, resistant,
  and invasive, each with distinct drug sensitivity parameters, resistance levels,
  and metabolic profiles;
- Vasculature network providing substrate supply and drug clearance;
- Cell phase tracking: viable, hypoxic, necrotic, apoptotic;
- Interstitial fluid dynamics affecting agent and drug transport.

LAYER 2 — STIGMERGIC SIGNAL FIELD (104):
A shared multi-channel chemical signal array co-registered with the tumor grid,
implementing the following typed signal primitives (see Section D):
- Trail signal: encodes successful navigation paths to viable tumor cells;
- Alarm signal: encodes regions of toxicity, barrier, or agent loss;
- Recruitment signal: encodes high-value targets requiring concentrated attack.
Each channel decays exponentially with time constant tau (configurable per signal
type) and diffuses spatially at rate D_phero, creating natural gradient fields
that guide agent navigation without explicit path planning.

LAYER 3 — AUTONOMOUS AGENT LAYER (106):
Each agent (nanobot) 108 is an independent entity with:
- Position in continuous 2D/3D space within the tumor grid;
- Internal state: carrying_drug (boolean), drug_payload (float), energy (float);
- Sensing radius: reads pheromone field values within radius r_sense;
- Decision engine: either rule-based finite state machine or small LLM (local model);
- Actions: move (follow gradient or random), deliver_drug (to adjacent target cell),
  deposit_pheromone (typed signal at current position), report_to_queen.
Agents do NOT communicate directly with each other. All coordination is mediated
exclusively through Layer 2 signal field reads and writes.

LAYER 4 — HIERARCHICAL LLM COORDINATOR — THE QUEEN (110):
A large language model (LLM) component that:
- Receives periodic summary reports aggregated from all agent local observations;
- Issues episodic strategic guidance to the agent population via the signal field
  (e.g., boosting recruitment signal amplitude in a target zone, or issuing
  an alarm signal overlay across a toxic region);
- Maintains global tumor state awareness that individual agents cannot achieve;
- Adapts strategy based on observed kill rates, drug efficiency, and tumor response;
- Can receive natural language instructions from a supervising clinician.
In the preferred dual-LLM embodiment, the Queen uses a large model (e.g., 70B
parameter class) while individual agents optionally use smaller models (e.g., 7B
parameter class) for local decision-making, enabling cost-efficient hierarchical
reasoning.

OPTIONAL LAYER 5 — BLOCKCHAIN AUDIT LAYER (112):
An optional distributed ledger integration that:
- Records each drug delivery event as an immutable transaction, including: agent ID,
  target cell ID, drug amount, cell type, timestamp, and signal field state hash;
- Provides cryptographically tamper-evident audit trail of all therapeutic decisions;
- Enables post-hoc analysis of treatment delivery provenance;
- Uses zero-knowledge proofs (ZKPs) to verify simulation correctness and drug
  delivery claims without exposing underlying patient anatomical data on-chain.

### Section B: Physics-Based CED Baseline for Benchmarking

To quantify therapeutic advantage over current clinical standard of care, the
system includes a physics-validated CED simulation module implementing the
advection-diffusion-reaction equation on the same grid as the nanobot simulation:

  dC/dt = D_eff * nabla^2(C) - v * nabla(C) - (lambda + k_bbb) * C + S(x,t)

Parameters are drawn from clinical literature:
- D_eff = 5e-8 cm^2/s (effective diffusion, reduced by tortuosity factor 1.6)
- v = 0.2 µm/min (convection velocity under typical CED infusion pressure)
- lambda = 0.01/min (drug degradation, half-life ~70 min for carmustine-class agents)
- k_bbb = 0.005/min (vascular clearance rate)
- Infusion: 5 µL/min for 360 minutes (6 hours), normalized concentration C_0 = 1

The CED module and nanobot simulation are run on identical tumor geometries
(same cell positions, types, phases, and resistance levels), enabling direct
head-to-head comparison. Key comparison metrics:

a) Kill rate: fraction of initial tumor cells eliminated;
b) Drug efficiency: cells killed per unit drug administered/delivered;
c) Stem cell kill rate: fraction of CSCs eliminated (critical for recurrence);
d) Distribution coverage: fraction of tumor volume reached by therapeutic drug.

### Section C: BraTS MRI Segmentation Integration

For clinically realistic benchmarking, the system accepts tumor geometry derived
from the BraTS (Brain Tumor Segmentation) challenge dataset (Bakas et al., 2018,
Scientific Data 5:180119), which provides multi-modal MRI segmentation labels
for: enhancing tumor core, peritumoral edema, and necrotic core. The invention
includes a method for converting BraTS segmentation volumes to the agent simulation
grid, populating cells by region:
- Enhancing tumor core -> predominantly differentiated + resistant cells;
- Peritumoral edema -> invasive cells at infiltrating margin;
- Necrotic core -> necrotic phase cells (no drug needed, used for catheter placement
  in CED reference, avoided by nanobot agents).

### Section D: Typed Pheromone Communication Protocol

The invention defines a formal typed signal protocol for LLM swarm agents:

SIGNAL TYPE 1 — TRAIL (tau_trail = 30 min, D_trail = 0.5 µm^2/min):
Deposited by: agents successfully navigating to a viable tumor cell.
Read by: all agents seeking targets.
Semantics: "This path leads to killable tumor cells. Reinforce this route."
Analogous to: Lasius niger trail pheromone (2-methyl-4-heptanone).

SIGNAL TYPE 2 — ALARM (tau_alarm = 10 min, D_alarm = 2.0 µm^2/min):
Deposited by: agents detecting toxicity, barrier structures, or agent destruction.
Read by: all agents navigating nearby.
Semantics: "This region is dangerous. Avoid or approach with caution."
Analogous to: Solenopsis invicta alarm pheromone (4-methyl-3-heptanone).

SIGNAL TYPE 3 — RECRUITMENT (tau_recruit = 60 min, D_recruit = 1.0 µm^2/min):
Deposited by: agents that have identified a high-priority target (e.g., CSC cluster)
and require additional agents to converge for concentrated attack.
Read by: idle or low-priority agents.
Semantics: "High-value target detected at source. Rally here."
Analogous to: army ant recruitment pheromone cascade.

All signals are deposited to and read from the shared field array — no direct
agent-to-agent transmission occurs. This design is biologically plausible (chemical
signals in interstitial fluid), computationally scalable (O(1) read/write per agent
per timestep), and privacy-preserving (no agent needs to know the identity or
state of any other agent).

### Section E: Zero-Knowledge Proof Integration

In embodiments involving blockchain audit logging, the system generates
zero-knowledge proofs (ZKPs) using a SNARK (Succinct Non-interactive ARgument
of Knowledge) circuit that attests to the following statement:

  "Given public commitment H = hash(tumor_geometry, simulation_params),
   the simulation produced outcome O = {cells_killed, drug_efficiency, kill_rate}
   using protocol P = {agent_decisions, signal_field_history},
   without revealing the underlying patient anatomical data encoded in
   tumor_geometry."

This enables: (a) clinical trial auditability without patient data exposure;
(b) regulatory submission of simulation results with cryptographic integrity
guarantees; (c) multi-institutional collaboration where each site can verify
simulation claims without sharing patient MRI data.

---

## CLAIMS

### Independent Claims

**Claim 1.**
A system for targeted therapeutic delivery comprising:
  a) a plurality of autonomous agents, each agent having an independent decision
     engine, a position in a continuous spatial domain, and a drug delivery payload;
  b) a stigmergic chemical signal field co-registered with the spatial domain,
     comprising one or more signal channels each characterized by a spatial
     diffusion coefficient and temporal decay constant;
  c) a hierarchical coordinator configured to receive aggregated state reports
     from the plurality of agents and issue strategic guidance;
wherein each agent reads signal field values within a local sensing radius and
writes signal field values at its current position as the sole mechanism of
inter-agent coordination, and wherein no direct peer-to-peer communication
channel exists between any two agents.

**Claim 7.**
A communication protocol for autonomous agent swarms comprising:
  a) a trail signal primitive deposited by an agent upon successful completion
     of a navigation path to a target, encoding path success with temporal decay
     constant tau_trail;
  b) an alarm signal primitive deposited by an agent upon detection of a hazard,
     toxicity threshold, or agent destruction event, encoding danger with faster
     temporal decay constant tau_alarm < tau_trail and higher spatial diffusion
     coefficient D_alarm > D_trail;
  c) a recruitment signal primitive deposited by an agent upon identification of
     a high-priority target requiring concentrated multi-agent response, with
     longer temporal persistence tau_recruit > tau_trail;
wherein all signal primitives are deposited to and read from a shared spatial
field array, and wherein no agent transmits signals directly to any other agent.

**Claim 6.**
A method of benchmarking a multi-agent therapeutic delivery system against a
convection-enhanced delivery (CED) baseline, comprising:
  a) generating a shared tumor geometry from brain tumor segmentation data,
     wherein the geometry specifies positions, types, phases, and resistance
     levels of individual tumor cells;
  b) running a physics-based CED simulation on the shared geometry, wherein drug
     transport is governed by the advection-diffusion-reaction equation with
     clinically validated parameters for effective diffusion coefficient, convective
     velocity, drug degradation rate, and vascular clearance rate;
  c) running the multi-agent therapeutic delivery system on the same shared geometry
     without modification to cell positions or properties;
  d) computing comparative metrics including: kill rate, drug efficiency defined
     as cells killed per unit drug administered, stem cell kill rate, and
     distribution volume coverage;
wherein the shared tumor geometry ensures that differences in outcome metrics
are attributable solely to the delivery method rather than tumor geometry variation.

### Dependent Claims

**Claim 2.**
The system of claim 1, wherein the signal field state is recorded at each
simulation timestep as a transaction on a distributed ledger, the transaction
comprising: a hash of the current signal field array, a list of agent drug
delivery events with target cell identifiers and drug amounts, and a block
timestamp; such that the complete therapeutic delivery audit trail is immutable
and cryptographically tamper-evident.

**Claim 3.**
The system of claim 2, wherein ledger transactions are accompanied by a
zero-knowledge proof attesting to the correctness of the simulation computation
given a public commitment to the tumor geometry parameters, such that a verifier
can confirm simulation integrity and delivery outcomes without access to
patient anatomical data encoded in the tumor geometry commitment.

**Claim 4.**
The system of claim 1, wherein:
  a) the hierarchical coordinator employs a first large language model having
     at least 10 billion parameters to generate episodic strategic guidance
     expressed as natural language instructions or signal field amplitude
     modifications, based on aggregated tumor state summaries presented as
     structured prompts;
  b) each autonomous agent optionally employs a second language model having
     fewer parameters than the first model for local decision-making, wherein
     the second model receives as input the agent's local sensor observations
     including signal field readings, adjacent cell type classifications, and
     current drug payload status;
  c) the hierarchical coordinator issues guidance at a lower temporal frequency
     than individual agent decision cycles, enabling global strategic adaptation
     without imposing synchronization latency on individual agents.

**Claim 5.**
The system of claim 1, applied to treatment of glioblastoma multiforme, wherein:
  a) the spatial domain represents a portion of brain parenchyma containing a
     GBM tumor, with a substrate diffusion model for oxygen and therapeutic agents;
  b) the plurality of agents navigate the tumor microenvironment and selectively
     deliver drug payloads to target cells, prioritizing: (i) cancer stem cells
     with sensitivity multiplier less than 0.5 relative to differentiated cells,
     (ii) viable cells over necrotic or apoptotic cells, and (iii) cells at the
     infiltrating tumor margin that are inaccessible to CED catheter placement;
  c) agents deposit trail signals upon successful delivery to viable tumor cells,
     alarm signals upon detecting necrotic core regions that waste drug payload,
     and recruitment signals upon identifying cancer stem cell clusters;
  d) the hierarchical coordinator receives tumor kill rate metrics and adapts
     the signal field amplitude profile to redirect agent concentration toward
     under-treated tumor subregions.

**Claim 8.**
The system of claim 1, wherein the decision engine of each autonomous agent
is a finite state machine comprising the states: SEARCHING (following trail
gradient or random walk), TARGETING (navigating toward high-signal voxel),
DELIVERING (adjacent to target cell, administering drug payload), RETURNING
(moving toward drug resupply depot), and ALARMED (retreating from high-alarm zone).

**Claim 9.**
The system of claim 4, wherein the natural language instructions issued by the
hierarchical coordinator are selected from a strategy set comprising:
  AGGRESSIVE_CORE — increase agent concentration in tumor core, maximize total kill;
  STEM_CELL_HUNT — redirect all agents toward cancer stem cell clusters detected
    by signal field recruitment signal density;
  MARGIN_SWEEP — distribute agents to tumor periphery to target invasive cells;
  CONSERVE_DRUG — reduce drug delivery rate and extend coverage area;
wherein strategy selection is made by the large language model based on observed
kill rate trajectories, drug efficiency trends, and remaining viable cell counts.

**Claim 10.**
The method of claim 6, wherein the brain tumor segmentation data is derived from
the BraTS (Brain Tumor Segmentation) MRI dataset, and wherein the shared tumor
geometry populates: enhancing tumor core regions with differentiated and resistant
cell types, peritumoral edema regions with invasive cell types, and necrotic core
regions with necrotic phase cells, such that the simulated tumor geometry
approximates the biological heterogeneity of patient GBM tumors as characterized
by multi-parametric MRI.

**Claim 11.**
The system of claim 2, wherein the distributed ledger is a public or private
blockchain network, and wherein each drug delivery event recorded on the ledger
includes: a unique agent identifier, a target cell identifier, a drug dose amount,
a cell type label (stem/differentiated/resistant/invasive), the signal field values
read by the agent at the time of delivery, and the strategic guidance message
most recently issued by the hierarchical coordinator, enabling complete
reproducibility and auditability of therapeutic delivery decisions.

**Claim 12.**
The system of claim 1, wherein the signal field is implemented as a 2D or 3D
numpy array co-registered with the simulation grid, wherein signal deposition
is an O(1) write operation at the agent's grid voxel, and wherein signal reading
is a vectorized operation over all voxels within the sensing radius, such that
the total computational complexity of inter-agent coordination scales as O(N)
in the number of agents rather than O(N^2) as would be required for direct
peer-to-peer communication.

---

## ABSTRACT

A system and method for targeted therapeutic delivery in which a plurality of
autonomous agents coordinate exclusively through a shared stigmergic chemical
signal field, with no direct peer-to-peer communication. A hierarchical large
language model coordinator issues episodic strategic guidance to the agent
population. Applied to glioblastoma multiforme treatment, agents navigate the
tumor microenvironment and selectively deliver drug to cancer stem cells,
differentiated tumor cells, resistant clones, and invasive margin cells in
a biologically-informed manner that is inaccessible to current clinical standard
of care (CED). Optional embodiments record all therapeutic delivery decisions
on a distributed ledger with zero-knowledge proof verification. A physics-based
CED benchmarking module enables quantitative comparison of the system against
clinical standard of care on identical tumor geometry.

---

## PRIOR ART DIFFERENTIATION

The following table summarizes how the present invention differs from the most
relevant prior art:

| Prior Art System         | Key Limitation vs. Present Invention                         |
|--------------------------|--------------------------------------------------------------|
| AutoGen (Microsoft)      | Uses direct agent-to-agent message passing; no biological    |
|                          | substrate model; no typed stigmergic signal field; not       |
|                          | applied to therapeutic delivery; no CED benchmarking.        |
| CrewAI                   | Role-based direct communication; sequential task delegation; |
|                          | no pheromone field; no drug delivery physics; no ZKP audit.  |
| LangChain Agents         | Tool-use framework; no multi-agent coordination; no stigmergy|
|                          | or swarm behavior; no biological simulation layer.           |
| PhysiCell / BioFVM       | Passive cell simulation only; no autonomous therapeutic      |
|                          | agents; no LLM reasoning; no pheromone communication layer.  |
| Standard Swarm Robotics  | Fixed behavioral rules; no LLM reasoning capability; agents  |
| (ACO, PSO, etc.)         | cannot interpret complex sensor data or adapt strategy based |
|                          | on natural language clinician instructions; no blockchain.   |
| CED (clinical standard)  | Not an agent-based system; no cell-type targeting; no        |
|                          | feedback or adaptation; requires surgery; low drug           |
|                          | efficiency; cannot reach infiltrating margin cells.          |

The combination of: (1) stigmergy as the sole coordination primitive,
(2) typed biochemical signal protocol, (3) hierarchical dual-LLM architecture,
(4) biology-grounded tumor microenvironment model, (5) blockchain audit trail
with ZKP privacy, and (6) CED benchmarking methodology is novel and non-obvious
over any single prior art reference or obvious combination thereof.

---

## BRIEF DESCRIPTION OF DRAWINGS

Figure 1: System architecture overview showing the four principal layers:
          tumor microenvironment (102), stigmergic signal field (104),
          agent layer (106), and LLM coordinator (110).

Figure 2: Pheromone signal field visualization showing trail, alarm, and
          recruitment channel distributions during active tumor targeting.

Figure 3: CED vs. nanobot comparison: drug concentration spatial distribution
          at t=60min, t=180min, t=360min for CED (uniform pressure-driven spread)
          vs. agent-based delivery (targeted to viable cell clusters).

Figure 4: Kill rate curves comparing CED baseline vs. nanobot swarm, showing
          superior stem cell kill rate for agent-based delivery.

Figure 5: Blockchain audit trail structure showing transaction schema and
          ZKP verification circuit.

Figure 6: BraTS MRI segmentation to simulation grid mapping pipeline.

---

## SEQUENCE OF EVENTS (Prosecution History Reference)

- November 3, 2025: BSN2025 conference disclosure (Claims 1 and 5 in part).
  Triggers 12-month grace period under 35 U.S.C. § 102(b)(1)(A) for the
  disclosed subject matter. Claims 2, 3, 4, 6, 7 were NOT disclosed and are
  not subject to this grace period as prior art disclosures by inventors.

- [Filing Date TBD]: This provisional application filed. All claims herein are
  entitled to this date as priority date.

- [Filing Date + 12 months]: Non-provisional application deadline (35 U.S.C. § 111(a)).
  Claims must be filed within this window to preserve provisional priority.

---

## DRAWINGS INCORPORATED BY REFERENCE

All simulation output figures, architecture diagrams, and flowcharts generated
by the Antelligence system and referenced herein are incorporated by reference.

---

*[END OF PROVISIONAL PATENT APPLICATION]*

*This document is a DRAFT prepared for inventor review. It does not constitute
legal advice and should be reviewed by a registered patent attorney or agent
before filing. Claim language should be reviewed for consistency with enablement
and written description requirements of 35 U.S.C. § 112.*
